This site is intended for healthcare professionals

FDA grants emergency use authorisation for ID NOW COVID-19 EUA Test for coronavirus.- Abbott

Read time: 1 mins
Published:29th Mar 2020
Abbott announced that the FDA has issued Emergency Use Authorization (EUA) for ID NOW COVID-19 EUA Test, a molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes. The test will run on the company's ID NOW platform, providing rapid results in a wide range of healthcare settings such as physicians' offices, urgent care clinics and hospital emergency departments.Comment: Abbott will be making ID NOW COVID-19 tests available next week (April 2020) to healthcare providers in urgent care settings in the U.S., where the majority of ID NOW instruments are in use. the Abbott ID NOW COVID-19 test comes a week after the company launched its Abbott m2000 RealTime SARS-CoV-2 EUA test, which runs on the m2000 RealTime System located in hospital and reference labs around the world.
Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.